{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:19:55Z","timestamp":1792120795737,"version":"4.4.0"},"reference-count":278,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41573-018-0003-2","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T11:08:01Z","timestamp":1543921681000},"page":"139-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["Therapeutic strategies for sickle cell disease: towards a multi-agent approach"],"prefix":"10.1038","volume":"18","author":[{"given":"Marilyn J.","family":"Telen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punam","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Vercellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1056\/NEJM199709113371107","volume":"337","author":"HF Bunn","year":"1997","unstructured":"Bunn, H. F. Pathogenesis and treatment of sickle cell disease. N. Engl. J. Med. 337, 762\u2013769 (1997).","journal-title":"N. Engl. J. Med."},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","volume":"376","author":"DC Rees","year":"2010","unstructured":"Rees, D. C., Williams, T. N. & Gladwin, M. T. Sickle-cell disease. Lancet 376, 2018\u20132031 (2010).","journal-title":"Lancet"},{"key":"3_CR3","first-page":"1639","volume":"330","author":"OS Platt","year":"1994","unstructured":"Platt, O. S. et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330, 1639\u20131644 (1994).","journal-title":"Life expectancy and risk factors for early death. N. Engl. J. Med."},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ajh.21408","volume":"84","author":"TL Kauf","year":"2009","unstructured":"Kauf, T. L., Coates, T. D., Huazhi, L., Mody-Patel, N. & Hartzema, A. G. The cost of health care for children and adults with sickle cell disease. Am. J. Hematol. 84, 323\u2013327 (2009).","journal-title":"Am. J. Hematol."},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ajh.23683","volume":"89","author":"H Elmariah","year":"2014","unstructured":"Elmariah, H. et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am. J. Hematol. 89, 530\u2013535 (2014).","journal-title":"Am. J. Hematol."},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjh.14167","volume":"174","author":"SD Arnold","year":"2016","unstructured":"Arnold, S. D., Bhatia, M., Horan, J. & Krishnamurti, L. Haematopoietic stem cell transplantation for sickle cell disease \u2014 current practice and new approaches. Br. J. Haematol. 174, 515\u2013525 (2016).","journal-title":"Br. J. Haematol."},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.hoc.2014.08.014","volume":"28","author":"CD Fitzhugh","year":"2014","unstructured":"Fitzhugh, C. D., Abraham, A. A., Tisdale, J. F. & Hsieh, M. M. Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematol. Oncol. Clin. North Amer. 28, 1171\u20131185 (2014).","journal-title":"Hematol. Oncol. Clin. North Amer."},{"key":"3_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27263","volume":"65","author":"ML Hulbert","year":"2018","unstructured":"Hulbert, M. L. & Shenoy, S. Hematopoietic stem cell transplantation for sickle cell disease: progress and challenges. Pediatr. Blood Cancer 65, e27263 (2018).","journal-title":"Pediatr. Blood Cancer"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.hemonc.2017.05.008","volume":"10","author":"AA Kassim","year":"2017","unstructured":"Kassim, A. A. & Sharma, D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol. Oncol. Stem Cell Ther. 10, 259\u2013266 (2017).","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"3_CR10","first-page":"CD007001","volume":"19","author":"C Oringanje","year":"2016","unstructured":"Oringanje, C., Nemecek, E. & Oniyangi, O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database Syst. Rev. 19, CD007001 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MOH.0000000000000136","volume":"22","author":"MC Walters","year":"2015","unstructured":"Walters, M. C. Update of hematopoietic cell transplantation for sickle cell disease. Curr. Opin. Hematol. 22, 227\u2013233 (2015).","journal-title":"Curr. Opin. Hematol."},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","volume":"129","author":"WA Eaton","year":"2017","unstructured":"Eaton, W. A. & Bunn, H. F. Treating sickle cell disease by targeting HbS polymerization. Blood 129, 2719\u20132726 (2017).","journal-title":"Blood"},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.hoc.2013.11.005","volume":"28","author":"RP Hebbel","year":"2014","unstructured":"Hebbel, R. P. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol. Oncol. Clin. North Amer. 28, 181\u2013198 (2014).","journal-title":"Hematol. Oncol. Clin. North Amer."},{"key":"3_CR14","first-page":"271","volume":"9","author":"RP Hebbel","year":"2009","unstructured":"Hebbel, R. P., Vercellotti, G. & Nath, K. A. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovascular Hematol. Disord. Drug Targets 9, 271\u2013292 (2009).","journal-title":"Disord. Drug Targets"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ajh.21952","volume":"86","author":"RP Hebbel","year":"2011","unstructured":"Hebbel, R. P. Reconstructing sickle cell disease: a data-based analysis of the \u201chyperhemolysis paradigm\u201d for pulmonary hypertension from the perspective of evidence-based medicine. Am. J. Hematol. 86, 123\u2013154 (2011).","journal-title":"Am. J. Hematol."},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/mic.11.2.129.151","volume":"11","author":"RP Hebbel","year":"2004","unstructured":"Hebbel, R. P., Osarogiagbon, R. & Kaul, D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11, 129\u2013151 (2004).","journal-title":"Microcirculation"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1182\/blood-2004-01-0042","volume":"104","author":"R Zennadi","year":"2004","unstructured":"Zennadi, R. et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-\u03b1v\u03b23 interactions. Blood 104, 3774\u20133781 (2004).","journal-title":"Blood"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood-2011-03-344440","volume":"119","author":"R Zennadi","year":"2012","unstructured":"Zennadi, R. et al. Erythrocyte plasma membrane-bound ERK1\/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood 119, 1217\u20131227 (2012).","journal-title":"Blood"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood-2012-07-441188","volume":"121","author":"A George","year":"2013","unstructured":"George, A. et al. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood 121, 2099\u20132107 (2013).","journal-title":"Blood"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/108155899904700307","volume":"47","author":"T Wun","year":"1999","unstructured":"Wun, T. et al. Platelet-erythrocyte adhesion in sickle cell disease. J. Investig. Med. 47, 121\u2013127 (1999).","journal-title":"J. Investig. Med."},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0022-2143(97)90005-6","volume":"129","author":"T Wun","year":"1997","unstructured":"Wun, T. et al. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J. Lab. Clin. Med. 129, 507\u2013516 (1997).","journal-title":"J. Lab. Clin. Med."},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00062752-200203000-00003","volume":"9","author":"PS Frenette","year":"2002","unstructured":"Frenette, P. S. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr. Opin. Hematol. 9, 101\u2013106 (2002).","journal-title":"Curr. Opin. Hematol."},{"key":"3_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/mic.11.2.167.177","volume":"11","author":"PS Frenette","year":"2004","unstructured":"Frenette, P. S. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation 11, 167\u2013177 (2004).","journal-title":"Microcirculation"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1073\/pnas.052522799","volume":"99","author":"A Turhan","year":"2002","unstructured":"Turhan, A., Weiss, L. A., Mohandas, N., Coller, B. S. & Frenette, P. S. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl Acad. Sci. USA 99, 3047\u20133051 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1365-2141.2008.07056.x","volume":"141","author":"JE Brittain","year":"2008","unstructured":"Brittain, J. E., Knoll, C. M., Ataga, K. I., Orringer, E. P. & Parise, L. V. Fibronectin bridges monocytes and reticulocytes via integrin \u03b14\u03b21. Br. J. Haematol. 141, 872\u2013881 (2008).","journal-title":"Br. J. Haematol."},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nm.1939","volume":"15","author":"A Hidalgo","year":"2009","unstructured":"Hidalgo, A. et al. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat. Med. 15, 384\u2013391 (2009).","journal-title":"Nat. Med."},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1182\/blood.V95.10.3232","volume":"95","author":"YT Shiu","year":"2000","unstructured":"Shiu, Y. T., Udden, M. M. & McIntire, L. V. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 95, 3232\u20133241 (2000).","journal-title":"Blood"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.bpj.2014.06.031","volume":"107","author":"H Li","year":"2014","unstructured":"Li, H. & Lykotrafitis, G. Erythrocyte membrane model with explicit description of the lipid bilayer and the spectrin network. Biophys. J. 107, 642\u2013653 (2014).","journal-title":"Biophys. J."},{"key":"3_CR29","first-page":"860","volume-title":"Blood","author":"K de Jong","year":"2001","unstructured":"de Jong, K., Larkin, S. K., Styles, L. A., Bookchin, R. M. & Kuypers, F. A. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood 98, (860\u2013867 (2001)."},{"key":"3_CR30","first-page":"C403","volume":"269","author":"CH Joiner","year":"1995","unstructured":"Joiner, C. H., Jiang, M. & Franco, R. S. Deoxygenation-induced cation fluxes in sickle cells. IV. Modulation by external calcium. Am. J. Physiol. 269, C403\u2013409 (1995).","journal-title":"Modulation by external calcium. Am. J. Physiol."},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood-2015-04-637702","volume":"126","author":"TJ Mankelow","year":"2015","unstructured":"Mankelow, T. J. et al. Autophagic vesicles on mature human reticulocytes explain phosphatidylserine-positive red cells in sickle cell disease. Blood 126, 1831\u20131834 (2015).","journal-title":"Blood"},{"key":"3_CR32","first-page":"147","volume":"50","author":"FA Kuypers","year":"2004","unstructured":"Kuypers, F. A. & de Jong, K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell. Mol. Biol. 50, 147\u2013158 (2004).","journal-title":"Cell. Mol. Biol."},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","volume":"110","author":"J Villagra","year":"2007","unstructured":"Villagra, J. et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110, 2166\u20132172 (2007).","journal-title":"Blood"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.V81.8.2137.2137","volume":"81","author":"HA Brittain","year":"1993","unstructured":"Brittain, H. A., Eckman, J. R., Swerlick, R. A., Howard, R. J. & Wick, T. M. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 81, 2137\u20132143 (1993).","journal-title":"Blood"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.V96.3.1119","volume":"96","author":"BN Setty","year":"2000","unstructured":"Setty, B. N., Kulkarni, S., Rao, A. K. & Stuart, M. J. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood 96, 1119\u20131124 (2000).","journal-title":"Blood"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1182\/blood-2015-01-625707","volume":"126","author":"PI Arumugam","year":"2015","unstructured":"Arumugam, P. I. et al. Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood 126, 1844\u20131855 (2015).","journal-title":"Blood"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/01.ATV.0000220374.00602.a2","volume":"26","author":"SP Lee","year":"2006","unstructured":"Lee, S. P., Ataga, K. I., Orringer, E. P., Phillips, D. R. & Parise, L. V. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler. Thromb. Vasc. Biol. 26, 1626\u20131631 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2141.2007.06787.x","volume":"139","author":"SP Lee","year":"2007","unstructured":"Lee, S. P. et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br. J. Haematol. 139, 612\u2013620 (2007).","journal-title":"Br. J. Haematol."},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1161\/ATVBAHA.110.211615","volume":"30","author":"R Polanowska-Grabowska","year":"2010","unstructured":"Polanowska-Grabowska, R. et al. P-Selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler. Thromb. Vasc. Biol. 30, 2392\u20132399 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"3_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89761","volume":"2","author":"MF Bennewitz","year":"2017","unstructured":"Bennewitz, M. F. et al. Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight 2, e89761 (2017).","journal-title":"JCI Insight"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.3324\/haematol.2014.108555","volume":"99","author":"VM Dominical","year":"2014","unstructured":"Dominical, V. M. et al. Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. Haematologica 99, e214\u2013217 (2014).","journal-title":"Haematologica"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2008-01-134346","volume":"112","author":"R Zennadi","year":"2008","unstructured":"Zennadi, R., Chien, A., Xu, K., Batchvarova, M. & Telen, M. J. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 112, 3474\u20133483 (2008).","journal-title":"Blood"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1172\/JCI26857","volume":"116","author":"JD Belcher","year":"2006","unstructured":"Belcher, J. D. et al. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J. Clin. Invest. 116, 808\u2013816 (2006).","journal-title":"J. Clin. Invest."},{"key":"3_CR44","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1172\/JCI64578","volume":"123","author":"S Ghosh","year":"2013","unstructured":"Ghosh, S. et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J. Clin. Invest. 123, 4809\u20134820 (2013).","journal-title":"J. Clin. Invest."},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","volume":"123","author":"JD Belcher","year":"2014","unstructured":"Belcher, J. D. et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 123, 377\u2013390 (2014).","journal-title":"Blood"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1182\/blood-2011-06-361642","volume":"120","author":"CJ Bean","year":"2012","unstructured":"Bean, C. J. et al. Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood 120, 3822\u20133828 (2012).","journal-title":"Blood"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"831596","DOI":"10.1155\/2013\/831596","volume":"2013","author":"JD Belcher","year":"2013","unstructured":"Belcher, J. D., Nath, K. A. & Vercellotti, G. M. Vasculotoxic and proinflammatory effects of plasma heme: cell signaling and cytoprotective responses. ISRN Oxidative Med. 2013, 831596 (2013).","journal-title":"ISRN Oxidative Med."},{"key":"3_CR48","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1073\/pnas.76.2.670","volume":"76","author":"RL Nagel","year":"1979","unstructured":"Nagel, R. L. et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc. Natl Acad. Sci. USA 76, 670\u2013672 (1979).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","volume":"118","author":"I Akinsheye","year":"2011","unstructured":"Akinsheye, I. et al. Fetal hemoglobin in sickle cell anemia. Blood 118, 19\u201327 (2011).","journal-title":"Blood"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/ajh.24906","volume":"92","author":"JH Estepp","year":"2017","unstructured":"Estepp, J. H. et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am. J. Hematol. 92, 1333\u20131339 (2017).","journal-title":"Am. J. Hematol."},{"key":"3_CR51","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood.V63.4.921.921","volume":"63","author":"DR Powars","year":"1984","unstructured":"Powars, D. R., Weiss, J. N., Chan, L. S. & Schroeder, W. A. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 63, 921\u2013926 (1984).","journal-title":"Blood"},{"key":"3_CR52","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1073\/pnas.80.15.4842","volume":"80","author":"S Charache","year":"1983","unstructured":"Charache, S. et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the \u03b3-\u03b4-\u03b2-globin gene complex. Proc. Natl Acad. Sci. USA 80, 4842\u20134846 (1983).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3_CR53","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1073\/pnas.79.14.4428","volume":"79","author":"J DeSimone","year":"1982","unstructured":"DeSimone, J., Heller, P., Hall, L. & Zwiers, D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc. Natl Acad. Sci. USA 79, 4428\u20134431 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3_CR54","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1056\/NEJM198212093072401","volume":"307","author":"TJ Ley","year":"1982","unstructured":"Ley, T. J. et al. 5-Azacytidine selectively increases \u03b3-globin synthesis in a patient with \u03b2+ thalassemia. N. Engl. J. Med. 307, 1469\u20131475 (1982).","journal-title":"N. Engl. J. Med."},{"key":"3_CR55","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","volume":"14","author":"PT McGann","year":"2015","unstructured":"McGann, P. T. & Ware, R. E. Hydroxyurea therapy for sickle cell anemia. Expert Opin. Drug Saf. 14, 1749\u20131758 (2015).","journal-title":"Expert Opin. Drug Saf"},{"key":"3_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002382","volume":"14","author":"R Molokie","year":"2017","unstructured":"Molokie, R. et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLOS Med. 14, e1002382 (2017).","journal-title":"PLOS Med."},{"key":"3_CR57","first-page":"1790","volume":"93","author":"GF Atweh","year":"1999","unstructured":"Atweh, G. F. et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93, 1790\u20131797 (1999).","journal-title":"Blood"},{"key":"3_CR58","doi-asserted-by":"publisher","first-page":"E255","DOI":"10.1002\/ajh.23533","volume":"88","author":"A Kutlar","year":"2013","unstructured":"Kutlar, A. et al. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am. J. Hematol. 88, E255\u2013E260 (2013).","journal-title":"Am. J. Hematol."},{"key":"3_CR59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ajh.23725","volume":"89","author":"ME Reid","year":"2014","unstructured":"Reid, M. E. et al. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am. J. Hematol. 89, 709\u2013713 (2014).","journal-title":"Am. J. Hematol."},{"key":"3_CR60","doi-asserted-by":"publisher","first-page":"12617","DOI":"10.1073\/pnas.1006774107","volume":"107","author":"JE Bradner","year":"2010","unstructured":"Bradner, J. E. et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. Natl Acad. Sci. USA 107, 12617\u201312622 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nm.3101","volume":"19","author":"L Shi","year":"2013","unstructured":"Shi, L., Cui, S., Engel, J. D. & Tanabe, O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat. Med. 19, 291\u2013294 (2013).","journal-title":"Nat. Med."},{"key":"3_CR62","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.exphem.2015.04.005","volume":"43","author":"A Rivers","year":"2015","unstructured":"Rivers, A. et al. RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases \u03b3-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model. Exp. Hematol. 43, 546\u2013553 (2015).","journal-title":"Exp. Hematol."},{"key":"3_CR63","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1182\/blood-2015-02-626259","volume":"126","author":"S Cui","year":"2015","unstructured":"Cui, S. et al. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood 126, 386\u2013396 (2015).","journal-title":"Blood"},{"key":"3_CR64","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/ajh.24879","volume":"92","author":"Y Dai","year":"2017","unstructured":"Dai, Y., Chen, T., Ijaz, H., Cho, E. H. & Steinberg, M. H. SIRT1 activates the expression of fetal hemoglobin genes. Am. J. Hematol. 92, 1177\u20131186 (2017).","journal-title":"Am. J. Hematol."},{"key":"3_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.exphem.2017.10.003","volume":"58","author":"C Lanaro","year":"2018","unstructured":"Lanaro, C. et al. A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes. Exp. Hematol. 58, 35\u201338 (2018).","journal-title":"Exp. Hematol."},{"key":"3_CR66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bcmd.2015.11.007","volume":"58","author":"A Theodorou","year":"2016","unstructured":"Theodorou, A. et al. The investigation of resveratrol and analogs as potential inducers of fetal hemoglobin. Blood Cells Mol. Dis. 58, 6\u201312 (2016).","journal-title":"Blood Cells Mol. Dis."},{"key":"3_CR67","doi-asserted-by":"publisher","first-page":"96409","DOI":"10.1172\/jci.insight.96409","volume":"2","author":"S Krishnamoorthy","year":"2017","unstructured":"Krishnamoorthy, S. et al. Dimethyl fumarate increases fetal hemoglobin, provides heme detoxification, and corrects anemia in sickle cell disease. JCI Insight 2, 96409 (2017).","journal-title":"JCI Insight"},{"key":"3_CR68","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ajh.24750","volume":"92","author":"E Gomperts","year":"2017","unstructured":"Gomperts, E. et al. The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso-occlusive crises. Am. J. Hematol. 92, 569\u2013582 (2017).","journal-title":"Am. J. Hematol."},{"key":"3_CR69","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1182\/blood-2013-02-486282","volume":"122","author":"JD Belcher","year":"2013","unstructured":"Belcher, J. D. et al. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood 122, 2757\u20132764 (2013).","journal-title":"Blood"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood.V122.21.2205.2205","volume":"122","author":"J Howard","year":"2013","unstructured":"Howard, J. et al. Safety and tolerability of MP4CO: A dose escalation study In stable patients with sickle cell disease. Blood 122, 2205 (2013).","journal-title":"Blood"},{"key":"3_CR71","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/aor.12341","volume":"38","author":"H Misra","year":"2014","unstructured":"Misra, H., Lickliter, J., Kazo, F. & Abuchowski, A. PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial. Artif. Organs 38, 702\u2013707 (2014).","journal-title":"Artif. Organs"},{"key":"3_CR72","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/978-1-4939-3023-4_58","volume":"876","author":"A Abuchowski","year":"2016","unstructured":"Abuchowski, A. PEGylated bovine carboxyhemoglobin (SANGUINATE): results of clinical safety testing and use in patients. Adv. Exp. Med. Biol. 876, 461\u2013467 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"3_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood.V128.22.121.121","volume":"128","author":"R Swift","year":"2016","unstructured":"Swift, R. et al. SCD-101: a new anti-sickling drug reduces pain and fatigue and improves red blood cell shape in peripheral blood of patients with sickle cell disease. Blood 128, 121\u2013121 (2016).","journal-title":"Blood"},{"key":"3_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1365-2141.2002.03593.x","volume":"118","author":"EW Iyamu","year":"2002","unstructured":"Iyamu, E. W., Turner, E. A. & Asakura, T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br. J. Haematol. 118, 337\u2013343 (2002).","journal-title":"Br. J. Haematol."},{"key":"3_CR75","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1078\/0944-7113-00040","volume":"8","author":"C Wambebe","year":"2001","unstructured":"Wambebe, C. et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine 8, 252\u2013261 (2001).","journal-title":"Phytomedicine"},{"key":"3_CR76","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1182\/blood.V128.22.2488.2488","volume":"128","author":"J Lehrer-Graiwer","year":"2016","unstructured":"Lehrer-Graiwer, J. et al. Long-term dosing in sickle cell disease subjects with GBT440, a novel HbS polymerization inhibitor. Blood 128, 2488 (2016).","journal-title":"Blood"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ajh.24975","volume":"93","author":"RP Hebbel","year":"2018","unstructured":"Hebbel, R. P. & Hedlund, B. E. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. Am. J. Hematol. 93, 321\u2013325 (2018).","journal-title":"Am. J. Hematol."},{"key":"3_CR78","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood-2007-04-081703","volume":"111","author":"CR Morris","year":"2008","unstructured":"Morris, C. R. et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 111, 402\u2013410 (2008).","journal-title":"Blood"},{"key":"3_CR79","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/j.1742-4658.2011.08241.x","volume":"278","author":"S Whillier","year":"2011","unstructured":"Whillier, S., Garcia, B., Chapman, B. E., Kuchel, P. W. & Raftos, J. E. Glutamine and \u03b1-ketoglutarate as glutamate sources for glutathione synthesis in human erythrocytes. FEBS J. 278, 3152\u20133163 (2011).","journal-title":"FEBS J."},{"key":"3_CR80","first-page":"4","volume":"5","author":"Y Niihara","year":"2005","unstructured":"Niihara, Y. et al. L-Glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord. 5, 4 (2005).","journal-title":"BMC Blood Disord."},{"key":"3_CR81","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood.V124.21.86.86","volume":"124","author":"Y Niihara","year":"2014","unstructured":"Niihara, Y. et al. A Phase 3 study of L-glutamine therapy for sickle cell anemia and sickle \u00df-thalassemia. Blood 124, 86\u201386 (2014).","journal-title":"Blood"},{"key":"3_CR82","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/0148607117727271","volume":"41","author":"DW Wilmore","year":"2017","unstructured":"Wilmore, D. W. Food and Drug Administration approval of glutamine for sickle cell disease: success and precautions in glutamine research. JPEN J. Parenter Enteral Nutr. 41, 912\u2013917 (2017).","journal-title":"JPEN J. Parenter Enteral Nutr."},{"key":"3_CR83","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1096\/fj.04-3218fje","volume":"19","author":"KC Wood","year":"2005","unstructured":"Wood, K. C., Hebbel, R. P. & Granger, D. N. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 19, 989\u2013991 (2005).","journal-title":"FASEB J."},{"key":"3_CR84","doi-asserted-by":"publisher","first-page":"H293","DOI":"10.1152\/ajpheart.01150.2003","volume":"287","author":"DK Kaul","year":"2004","unstructured":"Kaul, D. K. et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. American journal of physiology. Heart Circulatory Physiol. 287, H293\u2013301 (2004).","journal-title":"Heart Circulatory Physiol."},{"key":"3_CR85","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00277-011-1404-z","volume":"91","author":"E Nur","year":"2012","unstructured":"Nur, E. et al. N-Acetylcysteine reduces oxidative stress in sickle cell patients. Ann. Hematol. 91, 1097\u20131105 (2012).","journal-title":"Ann. Hematol."},{"key":"3_CR86","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1182\/blood.V128.22.1299.1299","volume":"128","author":"HT Ozpolat","year":"2016","unstructured":"Ozpolat, H. T. et al. A pilot study of high-dose N-acetylcysteine infusion in patients with sickle cell disease. Blood 128, 1299\u20131299 (2016).","journal-title":"Blood"},{"key":"3_CR87","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/blood.V128.22.123.123","volume":"128","author":"JWR Sins","year":"2016","unstructured":"Sins, J. W. R. et al. N-acetylcysteine in patients with sickle cell disease: a randomized controlled trial. Blood 128, 123\u2013123 (2016).","journal-title":"Blood"},{"key":"3_CR88","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1182\/blood-2010-06-290643","volume":"116","author":"KL Wallace","year":"2010","unstructured":"Wallace, K. L. & Linden, J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116, 5010\u20135020 (2010).","journal-title":"Blood"},{"key":"3_CR89","first-page":"227","volume":"51","author":"EC Reilly","year":"2010","unstructured":"Reilly, E. C., Wands, J. R. & Brossay, L. Cytokine dependent and independent iNKT cell activation. Cytokine 51, 227\u2013231 (2010).","journal-title":"Cytokine dependent and independent iNKT cell activation. Cytokine"},{"key":"3_CR90","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1182\/blood-2012-11-465963","volume":"121","author":"JJ Field","year":"2013","unstructured":"Field, J. J. et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood 121, 3329\u20133334 (2013).","journal-title":"Blood"},{"key":"3_CR91","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","volume":"1","author":"JJ Field","year":"2017","unstructured":"Field, J. J. et al. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Adv. 1, 1645\u20131649 (2017).","journal-title":"Blood Adv."},{"key":"3_CR92","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/ajh.24856","volume":"12292","author":"A Solovey","year":"2017","unstructured":"Solovey, A. et al. A monocyte-TNF-endothelial activation axis in sickle transgenic mice: therapeutic benefit from TNF blockade. Am. J. Hemat. 12292, 1119\u20131130 (2017).","journal-title":"Am. J. Hemat."},{"key":"3_CR93","doi-asserted-by":"crossref","first-page":"bcr1020114889","DOI":"10.1136\/bcr.10.2011.4889","volume":"2011","author":"O Adelowo","year":"2011","unstructured":"Adelowo, O. & Edunjobi, A. S. Juvenile idiopathic arthritis coexisting with sickle cell disease: two case reports. BMJ Case Rep. 2011, bcr1020114889 (2011).","journal-title":"BMJ Case Rep."},{"key":"3_CR94","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.imbio.2012.07.024","volume":"217","author":"WB Gorsuch","year":"2012","unstructured":"Gorsuch, W. B., Chrysanthou, E., Schwaeble, W. J. & Stahl, G. L. The complement system in ischemia-reperfusion injuries. Immunobiology 217, 1026\u20131033 (2012).","journal-title":"Immunobiology"},{"key":"3_CR95","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1172\/JCI116706","volume":"92","author":"RH Wang","year":"1993","unstructured":"Wang, R. H., Phillips, G. Jr., Medof, M. E. & Mold, C. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J. Clin. Invest. 92, 1326\u20131335 (1993).","journal-title":"J. Clin. Invest."},{"key":"3_CR96","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1182\/blood.V89.4.1121","volume":"89","author":"RF Zwaal","year":"1997","unstructured":"Zwaal, R. F. & Schroit, A. J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89, 1121\u20131132 (1997).","journal-title":"Blood"},{"key":"3_CR97","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","volume":"120","author":"MJ Krisinger","year":"2012","unstructured":"Krisinger, M. J. et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120, 1717\u20131725 (2012).","journal-title":"Blood"},{"key":"3_CR98","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood.V128.22.158.158","volume":"128","author":"TR Schaid","year":"2016","unstructured":"Schaid, T. R. et al. Complement activation in a murine model of sickle cell disease: inhibition of vaso-occlusion by blocking C5 activation. Blood 128, 158 (2016).","journal-title":"Blood"},{"key":"3_CR99","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2141.2010.08480.x","volume":"153","author":"C Hoppe","year":"2011","unstructured":"Hoppe, C. et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br. J. Haematol. 153, 655\u2013663 (2011).","journal-title":"Br. J. Haematol."},{"key":"3_CR100","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/bjh.14580","volume":"177","author":"C Hoppe","year":"2017","unstructured":"Hoppe, C. et al. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br. J. Haematol. 177, 620\u2013629 (2017).","journal-title":"Br. J. Haematol."},{"key":"3_CR101","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.V92.7.2594","volume":"92","author":"AC Rybicki","year":"1998","unstructured":"Rybicki, A. C. & Benjamin, L. J. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood 92, 2594\u20132596 (1998).","journal-title":"Blood"},{"key":"3_CR102","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1172\/JCI33308","volume":"118","author":"N Sabaa","year":"2008","unstructured":"Sabaa, N. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J. Clin. Invest. 118, 1924\u20131933 (2008).","journal-title":"J. Clin. Invest."},{"key":"3_CR103","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1096\/fj.13-228577","volume":"27","author":"GN Prado","year":"2013","unstructured":"Prado, G. N., Romero, J. R. & Rivera, A. Endothelin-1 receptor antagonists regulate cell surface-associated protein disulfide isomerase in sickle cell disease. FASEB J. 27, 4619\u20134629 (2013).","journal-title":"FASEB J."},{"key":"3_CR104","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3324\/haematol.2016.156869","volume":"1028","author":"B Koehl","year":"2017","unstructured":"Koehl, B. et al. The endothelin B receptor plays a crucial role for the adhesion of neutrophils to the endothelium in sickle cell disease. Haematologica 1028, 1161\u20131172 (2017).","journal-title":"Haematologica"},{"key":"3_CR105","doi-asserted-by":"publisher","first-page":"147616","DOI":"10.1155\/2015\/147616","volume":"2015","author":"T Elisa","year":"2015","unstructured":"Elisa, T. et al. Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis. J. Immunol. Res. 2015, 147616 (2015).","journal-title":"J. Immunol. Res."},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2007-04-084061","volume":"111","author":"J Chang","year":"2008","unstructured":"Chang, J., Shi, P. A., Chiang, E. Y. & Frenette, P. S. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 111, 915\u2013923 (2008).","journal-title":"Blood"},{"key":"3_CR107","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/CIRCRESAHA.112.266411","volume":"110","author":"JE Jang","year":"2012","unstructured":"Jang, J. E., Hidalgo, A. & Frenette, P. S. Intravenous immunoglobulins modulate neutrophil activation and vascular injury through Fc\u03b3RIII and SHP-1. Circul. Res. 110, 1057\u20131066 (2012).","journal-title":"Circul. Res."},{"key":"3_CR108","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ajh.23956","volume":"90","author":"D Manwani","year":"2015","unstructured":"Manwani, D. et al. Single-dose intravenous \u03b3-globulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis. Am. J. Hematol. 90, 381\u2013385 (2015).","journal-title":"Am. J. Hematol."},{"key":"3_CR109","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2012-02-409524","volume":"120","author":"CB Almeida","year":"2012","unstructured":"Almeida, C. B. et al. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 120, 2879\u20132888 (2012).","journal-title":"Blood"},{"key":"3_CR110","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bcpt.12487","volume":"118","author":"MC Barbosa","year":"2016","unstructured":"Barbosa, M. C. et al. The effect of a selective inhibitor of phosphodiesterase-9 on oxidative stress, inflammation and cytotoxicity in neutrophils from patients with sickle cell anaemia. Bas. Clin. Pharmacol. Toxicol. 118, 271\u2013278 (2016).","journal-title":"Bas. Clin. Pharmacol. Toxicol."},{"key":"3_CR111","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1182\/blood.V128.22.268.268","volume":"128","author":"JC McArthur","year":"2016","unstructured":"McArthur, J. C. et al. Novel highly potent and selective PDE9 inhibitor for the treament of sickle cell disease. Blood 128, 268 (2016).","journal-title":"Blood"},{"key":"3_CR112","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.hoc.2013.11.008","volume":"28","author":"CR Morris","year":"2014","unstructured":"Morris, C. R. Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy. Hematol. Oncol. Clin. North Am. 28, 301\u2013321 (2014).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"3_CR113","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","volume":"98","author":"CR Morris","year":"2013","unstructured":"Morris, C. R. et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 98, 1375\u20131382 (2013).","journal-title":"Haematologica"},{"key":"3_CR114","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/blood-2014-12-616250","volume":"126","author":"CB Almeida","year":"2015","unstructured":"Almeida, C. B. et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood 126, 711\u2013720 (2015).","journal-title":"Blood"},{"key":"3_CR115","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.freeradbiomed.2004.02.073","volume":"37","author":"SB King","year":"2004","unstructured":"King, S. B. Nitric oxide production from hydroxyurea. Free Radic. Biol. Med. 37, 737\u2013744 (2004).","journal-title":"Free Radic. Biol. Med."},{"key":"3_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196455","volume":"13","author":"JD Belcher","year":"2018","unstructured":"Belcher, J. D. et al. Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: role of heme oxygenase-1 induction. PLOS ONE 13, e0196455 (2018).","journal-title":"PloS ONE"},{"key":"3_CR117","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2119\/molmed.2016.00063","volume":"22","author":"GM Vercellotti","year":"2016","unstructured":"Vercellotti, G. M. et al. Hepatic overexpression of hemopexin inhibits inflammation and vascular stasis in murine models of sickle cell disease. Mol. Med. 22, 437\u2013451 (2016).","journal-title":"Mol. Med."},{"key":"3_CR118","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1182\/blood.V128.22.2477.2477","volume":"128","author":"JD Belcher","year":"2016","unstructured":"Belcher, J. D. et al. Haptoglobin and hemopexin infusion efficiently activates the Nrf2\/HO-1 axis and inhibits inflammation and vaso-occlusion in murine sickle cell disease. Blood 128, 2477\u20132477 (2016).","journal-title":"Blood"},{"key":"3_CR119","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.12336","volume":"162","author":"E Sparkenbaugh","year":"2013","unstructured":"Sparkenbaugh, E. & Pawlinski, R. Interplay between coagulation and vascular inflammation in sickle cell disease. Br. J. Haematol. 162, 3\u201314 (2013).","journal-title":"Br. J. Haematol."},{"key":"3_CR120","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","volume":"127","author":"D Zhang","year":"2016","unstructured":"Zhang, D., Xu, C., Manwani, D. & Frenette, P. S. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood 127, 801\u2013809 (2016).","journal-title":"Blood"},{"key":"3_CR121","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1182\/blood.V88.6.2311.bloodjournal8862311","volume":"88","author":"BN Setty","year":"1996","unstructured":"Setty, B. N. & Stuart, M. J. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 88, 2311\u20132320 (1996).","journal-title":"Blood"},{"key":"3_CR122","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/MOH.0b013e328363442f","volume":"20","author":"MY Lim","year":"2013","unstructured":"Lim, M. Y., Ataga, K. I. & Key, N. S. Hemostatic abnormalities in sickle cell disease. Curr. Opin. Hematol. 20, 472\u2013477 (2013).","journal-title":"Curr. Opin. Hematol."},{"key":"3_CR123","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","volume":"30","author":"D Noubouossie","year":"2016","unstructured":"Noubouossie, D., Key, N. S. & Ataga, K. I. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 30, 245\u2013256 (2016).","journal-title":"Blood Rev."},{"key":"3_CR124","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/jth.13416","volume":"14","author":"MF Whelihan","year":"2016","unstructured":"Whelihan, M. F. et al. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. J. Thromb. Haemost. 14, 1941\u20131952 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"3_CR125","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0022-3476(85)80669-7","volume":"106","author":"EM Gordon","year":"1985","unstructured":"Gordon, E. M. et al. Reduction of contact factors in sickle cell disease. J. Pediatr. 106, 427\u2013430 (1985).","journal-title":"J. Pediatr."},{"key":"3_CR126","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/978-1-4615-9546-5_91","volume":"247B","author":"D LourenCo","year":"1989","unstructured":"LourenCo, D., Sampaio, M. U., Kerbauy, J. & Sampaio, C. A. Estimation of plasma kallikrein in sickle-cell anemia, and its relation to the coagulation and fibrinolytic systems. Adv. Exp. Med. Biol. 247B, 553\u2013557 (1989).","journal-title":"Adv. Exp. Med. Biol."},{"key":"3_CR127","first-page":"551","volume":"75","author":"RL Miller","year":"1983","unstructured":"Miller, R. L., Verma, P. S. & Adams, R. G. Studies of the kallikrein-kinin system in patients with sickle cell anemia. J. Natl Med. Associ. 75, 551\u2013556 (1983).","journal-title":"J. Natl Med. Associ."},{"key":"3_CR128","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1172\/JCI1932","volume":"101","author":"A Solovey","year":"1998","unstructured":"Solovey, A., Gui, L., Key, N. S. & Hebbel, R. P. Tissue factor expression by endothelial cells in sickle cell anemia. J. Clin. Invest. 101, 1899\u20131904 (1998).","journal-title":"J. Clin. Invest."},{"key":"3_CR129","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2003-10-3719","volume":"104","author":"A Solovey","year":"2004","unstructured":"Solovey, A. et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia\/reoxygenation and inhibited by lovastatin. Blood 104, 840\u2013846 (2004).","journal-title":"Blood"},{"key":"3_CR130","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM196307252690403","volume":"269","author":"JE Salvaggio","year":"1963","unstructured":"Salvaggio, J. E., Arnold, C. A. & Banov, C. H. Long-term anti-coagulation in sickle-cell disease. A clinical study. N. Engl. J. Med. 269, 182\u2013186 (1963).","journal-title":"N. Engl. J. Med."},{"key":"3_CR131","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1056\/NEJM195702212560807","volume":"256","author":"HT Adelson","year":"1957","unstructured":"Adelson, H. T. Long-term dicumarol administration as a therapeutic trial in sicklemia; report of a case. N. Engl. J. Med. 256, 353\u2013354 (1957).","journal-title":"N. Engl. J. Med."},{"key":"3_CR132","first-page":"574","volume":"66","author":"H Chaplin Jr","year":"1989","unstructured":"Chaplin, H. Jr. et al. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr. Med. J. 66, 574\u2013584 (1989).","journal-title":"East Afr. Med. J."},{"key":"3_CR133","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1160\/Th06-12-0718","volume":"98","author":"MH Qari","year":"2007","unstructured":"Qari, M. H. et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb. Haemostasis 98, 392\u2013396 (2007).","journal-title":"Thromb. Haemostasis"},{"key":"3_CR134","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1046\/j.1365-2141.1998.00627.x","volume":"100","author":"T Wun","year":"1998","unstructured":"Wun, T. et al. Platelet activation in patients with sickle cell disease. Br. J. Haematol. 100, 741\u2013749 (1998).","journal-title":"Br. J. Haematol."},{"key":"3_CR135","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1182\/blood-2003-04-1130","volume":"102","author":"H Kataoka","year":"2003","unstructured":"Kataoka, H. et al. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 102, 3224\u20133231 (2003).","journal-title":"Blood"},{"key":"3_CR136","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","volume":"3","author":"SR Coughlin","year":"2005","unstructured":"Coughlin, S. R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800\u20131814 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"3_CR137","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1161\/hh0801.089861","volume":"88","author":"J Loscalzo","year":"2001","unstructured":"Loscalzo, J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 88, 756\u2013762 (2001).","journal-title":"Circ. Res."},{"key":"3_CR138","first-page":"321","volume":"122","author":"K Kim","year":"2013","unstructured":"Kim, K. et al. Neutrophil Akt2 plays a critical role in heterotypic neutrophil-platelet interactions during vascular inflammation. Blood 122, 321\u2013321 (2013).","journal-title":"Blood"},{"key":"3_CR139","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1172\/JCI72305","volume":"124","author":"J Li","year":"2014","unstructured":"Li, J. et al. Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation. J. Clin. Invest. 124, 1483\u20131496 (2014).","journal-title":"J. Clin. Invest."},{"key":"3_CR140","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1182\/blood-2015-02-626234","volume":"126","author":"A Barazia","year":"2015","unstructured":"Barazia, A., Li, J., Kim, K., Shabrani, N. & Cho, J. Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice. Blood 126, 2511\u20132517 (2015).","journal-title":"Blood"},{"key":"3_CR141","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/pbc.25771","volume":"63","author":"CC Hoppe","year":"2016","unstructured":"Hoppe, C. C. et al. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: a global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatr. Blood Cancer 63, 299\u2013305 (2016).","journal-title":"Pediatr. Blood Cancer"},{"key":"3_CR142","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1512021","volume":"374","author":"MM Heeney","year":"2016","unstructured":"Heeney, M. M. et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N. Engl. J. Med. 374, 625\u2013635 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPH.0000000000000291","volume":"37","author":"L Styles","year":"2015","unstructured":"Styles, L. et al. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J. Pediatr. Hematol. Oncol. 37, 1\u20139 (2015).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"3_CR144","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.thromres.2013.12.008","volume":"133","author":"JA Jakubowski","year":"2014","unstructured":"Jakubowski, J. A. et al. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb. Res. 133, 190\u2013195 (2014).","journal-title":"Thromb. Res."},{"key":"3_CR145","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1756-8722-6-17","volume":"6","author":"T Wun","year":"2013","unstructured":"Wun, T. et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J. Hematol. Oncol. 6, 17 (2013).","journal-title":"J. Hematol. Oncol."},{"key":"3_CR146","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","volume":"116","author":"J Chang","year":"2010","unstructured":"Chang, J. et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 116, 1779\u20131786 (2010).","journal-title":"Blood"},{"key":"3_CR147","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","volume":"125","author":"MJ Telen","year":"2015","unstructured":"Telen, M. J. et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 125, 2656\u20132664 (2015).","journal-title":"Blood"},{"key":"3_CR148","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2017","unstructured":"Ataga, K. I. et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N. Engl. J. Med. 376, 429\u2013439 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3_CR149","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bjh.14303","volume":"175","author":"MJ Telen","year":"2016","unstructured":"Telen, M. J. et al. Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion. Br. J. Haematol. 175, 935\u2013948 (2016).","journal-title":"Br. J. Haematol."},{"key":"3_CR150","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4269\/ajtmh.2011.10-0256","volume":"84","author":"AM Leitgeb","year":"2011","unstructured":"Leitgeb, A. M. et al. Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates. Am. J. Trop. Med. Hyg. 84, 390\u2013396 (2011).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3_CR151","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/1076029614565880","volume":"22","author":"A Alshaiban","year":"2015","unstructured":"Alshaiban, A., Muralidharan-Chari, V., Nepo, A. & Mousa, S. A. Modulation of sickle red blood cell adhesion and its associated changes in biomarkers by sulfated nonanticoagulant heparin derivative. Clin. Appl. Thromb. Hemost. 22, 230\u2013238 (2015).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"3_CR152","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood.V95.2.368","volume":"95","author":"DK Kaul","year":"2000","unstructured":"Kaul, D. K. et al. Monoclonal antibodies to \u03b1V\u03b23 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 95, 368\u2013374 (2000).","journal-title":"Blood"},{"key":"3_CR153","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1182\/blood-2006-11-056101","volume":"110","author":"R Zennadi","year":"2007","unstructured":"Zennadi, R. et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 110, 2708\u20132717 (2007).","journal-title":"Blood"},{"key":"3_CR154","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tracli.2008.04.009","volume":"15","author":"R Zennadi","year":"2008","unstructured":"Zennadi, R. et al. Role and regulation of sickle red cell interactions with other cells: ICAM-4 and other adhesion receptors. Transfus. Clin. Biol. 15, 23\u201328 (2008).","journal-title":"Transfus. Clin. Biol."},{"key":"3_CR155","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cts.12005","volume":"5","author":"LM De Castro","year":"2012","unstructured":"De Castro, L. M., Zennadi, R., Jonassaint, J. C., Batchvarova, M. & Telen, M. J. Effect of propranolol as antiadhesive therapy in sickle cell disease. Clin. Transl Sci. 5, 437\u2013444 (2012).","journal-title":"Clin. Transl Sci."},{"key":"3_CR156","first-page":"00039","volume":"15","author":"LM De Castro","year":"2015","unstructured":"De Castro, L. M. Propranolol: anti-adhesive scd treatment. (a phase II study of propranolol as anti-adhesive therapy for sickle cell disease). J. Sick. Cell Dis. Hemoglobinopathies 15, 00039 (2015).","journal-title":"J. Sick. Cell Dis. Hemoglobinopathies"},{"key":"3_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/1559-0275-10-1","volume":"10","author":"EJ Soderblom","year":"2013","unstructured":"Soderblom, E. J. et al. Proteomic analysis of ERK1\/2-mediated human sickle red blood cell membrane protein phosphorylation. Clin. Proteomics 10, 1 (2013).","journal-title":"Clin. Proteom."},{"key":"3_CR158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110306","volume":"9","author":"R Zennadi","year":"2014","unstructured":"Zennadi, R. MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo. PLOS ONE 9, e110306 (2014).","journal-title":"PloS ONE"},{"key":"3_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094387","volume":"9","author":"V Allareddy","year":"2014","unstructured":"Allareddy, V. et al. Outcomes of acute chest syndrome in adult patients with sickle cell disease: predictors of mortality. PLOS ONE 9, e94387 (2014).","journal-title":"PloS ONE"},{"key":"3_CR160","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1365-2141.2006.06110.x","volume":"134","author":"KI Ataga","year":"2006","unstructured":"Ataga, K. I. et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br. J. Haematol. 134, 109\u2013115 (2006).","journal-title":"Br. J. Haematol."},{"key":"3_CR161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099489","volume":"9","author":"MT Gladwin","year":"2014","unstructured":"Gladwin, M. T. et al. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLOS ONE 9, e99489 (2014).","journal-title":"PloS ONE"},{"key":"3_CR162","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bjhh.2014.11.009","volume":"37","author":"AR Lima","year":"2015","unstructured":"Lima, A. R., Ribeiro, V. S. & Nicolau, D. I. Trends in mortality and hospital admissions of sickle cell disease patients before and after the newborn screening program in Maranhao. Brazil. Revista Brasileira Hematol. Hemoterapia 37, 12\u201316 (2015).","journal-title":"Revista Brasileira Hematol. Hemoterapia"},{"key":"3_CR163","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jped.2014.08.006","volume":"91","author":"AP Sabarense","year":"2014","unstructured":"Sabarense, A. P., Lima, G. O., Silva, L. M. & Viana, M. B. Characterization of mortality in children with sickle cell disease diagnosed through the Newborn Screening Program. J. Pediatr. 91, 242\u2013247 (2014).","journal-title":"J. Pediatr."},{"key":"3_CR164","first-page":"452","volume":"174","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Mortality of New York children with sickle cell disease identified through newborn screening. Genet. Med. 174, 452\u2013459 (2014).","journal-title":"Genet. Med."},{"key":"3_CR165","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood.V94.5.1555","volume":"94","author":"MJ Stuart","year":"1999","unstructured":"Stuart, M. J. & Setty, B. N. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 94, 1555\u20131560 (1999).","journal-title":"Blood"},{"key":"3_CR166","unstructured":"US Food and Frug Administration. FDA approved L-glutamine powder for the treatment of sickle cell disease. https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm566097.htm (FDA, 2017)."},{"key":"3_CR167","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1365-2141.2012.09105.x","volume":"157","author":"L Styles","year":"2012","unstructured":"Styles, L. et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br. J. Haematol. 157, 627\u2013636 (2012).","journal-title":"Br. J. Haematol."},{"key":"3_CR168","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00134-015-4060-2","volume":"41","author":"B Maitre","year":"2015","unstructured":"Maitre, B. et al. Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study. Intensive Care Med. 41, 2121\u20132129 (2015).","journal-title":"Intensive Care Med."},{"key":"3_CR169","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jtcvs.2007.02.043","volume":"134","author":"FE Barr","year":"2007","unstructured":"Barr, F. E. et al. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J. Thorac. Cardiovasc. Surg. 134, 319\u2013326 (2007).","journal-title":"J. Thorac. Cardiovascular Surg."},{"key":"3_CR170","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2141.2011.08827.x","volume":"155","author":"CT Quinn","year":"2011","unstructured":"Quinn, C. T. et al. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br. J. Haematol. 155, 263\u2013267 (2011).","journal-title":"Br. J. Haematol."},{"key":"3_CR171","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1097\/MPH.0b013e3181c29c52","volume":"32","author":"R Kumar","year":"2010","unstructured":"Kumar, R., Qureshi, S., Mohanty, P., Rao, S. P. & Miller, S. T. A short course of prednisone in the management of acute chest syndrome of sickle cell disease. J. Pediatr. Hematol. Oncol. 32, e91\u201394 (2010).","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"key":"3_CR172","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/pbc.21336","volume":"50","author":"JJ Strouse","year":"2008","unstructured":"Strouse, J. J., Takemoto, C. M., Keefer, J. R., Kato, G. J. & Casella, J. F. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr. Blood Cancer 50, 1006\u20131012 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"3_CR173","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1172\/JCI33308","volume":"118","author":"N Sabaa","year":"2008","unstructured":"Sabaa, N. et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J. Clin. Invest. 118, 1924\u20131933 (2008).","journal-title":"J. Clin. Invest."},{"key":"3_CR174","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1365-2141.2009.07906.x","volume":"147","author":"CP Minniti","year":"2009","unstructured":"Minniti, C. P. et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br. J. Haematol. 147, 737\u2013743 (2009).","journal-title":"Br. J. Haematol."},{"key":"3_CR175","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","volume":"149","author":"RJ Barst","year":"2010","unstructured":"Barst, R. J. et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br. J. Haematol. 149, 426\u2013435 (2010).","journal-title":"Br. J. Haematol."},{"key":"3_CR176","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2141.2011.08832.x","volume":"155","author":"AE Ashley-Koch","year":"2011","unstructured":"Ashley-Koch, A. E. et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br. J. Haematol. 155, 386\u2013394 (2011).","journal-title":"Br. J. Haematol."},{"key":"3_CR177","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ajh.21058","volume":"83","author":"LM De Castro","year":"2008","unstructured":"De Castro, L. M., Jonassaint, J. C., Graham, F. L., Ashley-Koch, A. & Telen, M. J. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am. J. Hematol. 83, 19\u201325 (2008).","journal-title":"Am. J. Hematol."},{"key":"3_CR178","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1056\/NEJM199204023261402","volume":"326","author":"RJ Falk","year":"1992","unstructured":"Falk, R. J. et al. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N. Engl. J. Med. 326, 910\u2013915 (1992).","journal-title":"N. Engl. J. Med."},{"key":"3_CR179","first-page":"CD009191","volume":"6","author":"TH Sasongko","year":"2015","unstructured":"Sasongko, T. H., Nagalla, S. & Ballas, S. K. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database Syst. Rev. 6, CD009191 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"3_CR180","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/ajh.23762","volume":"89","author":"KI Ataga","year":"2014","unstructured":"Ataga, K. I., Derebail, V. K. & Archer, D. R. The glomerulopathy of sickle cell disease. Am. J. Hematol. 89, 907\u2013914 (2014).","journal-title":"Am. J. Hematol."},{"key":"3_CR181","doi-asserted-by":"publisher","first-page":"E520","DOI":"10.1002\/ajh.24810","volume":"92","author":"CT Quinn","year":"2017","unstructured":"Quinn, C. T. et al. Losartan for the nephropathy of sickle cell anemia: a phase-2, multi-center trial. Am. J. Hematol. 92, E520\u2013E528 (2017).","journal-title":"Am. J. Hematol."},{"key":"3_CR182","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","volume":"7","author":"MC Walters","year":"2001","unstructured":"Walters, M. C. et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol. Blood Marrow Transplant. 7, 665\u2013673 (2001).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3_CR183","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2009-01-201863","volume":"114","author":"A Perumbeti","year":"2009","unstructured":"Perumbeti, A. et al. A novel human \u03b3-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114, 1174\u20131185 (2009).","journal-title":"Blood"},{"key":"3_CR184","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0958-1669(98)80029-3","volume":"9","author":"L Naldini","year":"1998","unstructured":"Naldini, L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 9, 457\u2013463 (1998).","journal-title":"Curr. Opin. Biotechnol."},{"key":"3_CR185","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1073\/pnas.96.6.2988","volume":"96","author":"SS Case","year":"1999","unstructured":"Case, S. S. et al. Stable transduction of quiescent CD34+CD38\u2013 human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl Acad. Sci. USA 96, 2988\u20132993 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3_CR186","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa, M. et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. Lancet 388, 476\u2013487 (2016).","journal-title":"Lancet"},{"key":"3_CR187","doi-asserted-by":"publisher","first-page":"1233151","DOI":"10.1126\/science.1233151","volume":"341","author":"A Aiuti","year":"2013","unstructured":"Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).","journal-title":"Science"},{"key":"3_CR188","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","volume":"377","author":"F Eichler","year":"2017","unstructured":"Eichler, F. et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 377, 1630\u20131638 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3_CR189","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.1171242","volume":"326","author":"N Cartier","year":"2009","unstructured":"Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818\u2013823 (2009).","journal-title":"Science"},{"key":"3_CR190","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","volume":"376","author":"JA Ribeil","year":"2017","unstructured":"Ribeil, J. A. et al. Gene therapy in a patient with sickle cell disease. N. Engl. J. Med. 376, 848\u2013855 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3_CR191","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","volume":"467","author":"M Cavazzana-Calvo","year":"2010","unstructured":"Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia. Nature 467, 318\u2013322 (2010).","journal-title":"Nature"},{"key":"3_CR192","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 378, 1479\u20131493 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3_CR193","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1126\/science.1065806","volume":"294","author":"R Pawliuk","year":"2001","unstructured":"Pawliuk, R. et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294, 2368\u20132371 (2001).","journal-title":"Science"},{"key":"3_CR194","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","volume":"125","author":"MD Hoban","year":"2015","unstructured":"Hoban, M. D. et al. Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells. Blood 125, 2597\u20132604 (2015).","journal-title":"Blood"},{"key":"3_CR195","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","volume":"102","author":"DN Levasseur","year":"2003","unstructured":"Levasseur, D. N., Ryan, T. M., Pawlik, K. M. & Townes, T. M. Correction of a mouse model of sickle cell disease: lentiviral\/antisickling \u03b2-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102, 4312\u20134319 (2003).","journal-title":"Blood"},{"key":"3_CR196","doi-asserted-by":"publisher","first-page":"27518","DOI":"10.1074\/jbc.M402578200","volume":"279","author":"DN Levasseur","year":"2004","unstructured":"Levasseur, D. N. et al. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. J. Biol. Chem. 279, 27518\u201327524 (2004).","journal-title":"J. Biol. Chem."},{"key":"3_CR197","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever, D. P. et al. CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature 539, 384\u2013389 (2016).","journal-title":"Nature"},{"key":"3_CR198","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3480","volume":"9","author":"SS De Ravin","year":"2017","unstructured":"De Ravin, S. S. et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci. Transl Med. 9, eaah3480 (2017).","journal-title":"Sci. Transl Med."},{"key":"3_CR199","first-page":"415","volume-title":"Nat. Med.","author":"TI Cornu","year":"2017","unstructured":"Cornu, T. I., Mussolino, C. & Cathomen, T. Refining strategies to translate genome editing to the clinic. Nat. Med. 23, (415\u2013423 (2017)."},{"key":"3_CR200","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.celrep.2017.06.064","volume":"20","author":"RO Bak","year":"2017","unstructured":"Bak, R. O. & Porteus, M. H. CRISPR-mediated integration of large gene cassettes using AAV donor vectors. Cell Rep. 20, 750\u2013756 (2017).","journal-title":"Cell Rep."},{"key":"3_CR201","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3408","volume":"33","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256\u20131263 (2015).","journal-title":"Nat. Biotechnol."},{"key":"3_CR202","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.04766","volume":"3","author":"S Lin","year":"2014","unstructured":"Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery. eLife 3, e04766 (2014).","journal-title":"eLife"},{"key":"3_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03475-7","volume":"9","author":"M Charpentier","year":"2018","unstructured":"Charpentier, M. et al. CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair. Nat. Commun. 9, 1133 (2018).","journal-title":"Nat. Commun."},{"key":"3_CR204","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nbt.4021","volume":"36","author":"MD Canny","year":"2018","unstructured":"Canny, M. D. et al. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat. Biotechnol. 36, 95\u2013102 (2018).","journal-title":"Nat. Biotechnol."},{"key":"3_CR205","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt.2916","volume":"32","author":"C Kuscu","year":"2014","unstructured":"Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat. Biotechnol. 32, 677\u2013683 (2014).","journal-title":"Nat. Biotechnol."},{"key":"3_CR206","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822\u2013826 (2013).","journal-title":"Nat. Biotechnol."},{"key":"3_CR207","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1172\/JCI81163","volume":"125","author":"A Basak","year":"2015","unstructured":"Basak, A. et al. BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations. J. Clin. Invest. 125, 2363\u20132368 (2015).","journal-title":"J. Clin. Invest."},{"key":"3_CR208","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1172\/JCI87885","volume":"126","author":"C Brendel","year":"2016","unstructured":"Brendel, C. et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J. Clin. Invest. 126, 3868\u20133878 (2016).","journal-title":"J. Clin. Invest."},{"key":"3_CR209","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm.4170","volume":"22","author":"EA Traxler","year":"2016","unstructured":"Traxler, E. A. et al. A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat. Med. 22, 987\u2013990 (2016).","journal-title":"Nat. Med."},{"key":"3_CR210","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/mt.2016.148","volume":"24","author":"MD Hoban","year":"2016","unstructured":"Hoban, M. D. et al. CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol. Ther. 24, 1561\u20131569 (2016).","journal-title":"Mol. Ther."},{"key":"3_CR211","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci. Transl Med. 8, 360ra134 (2016).","journal-title":"Sci. Transl Med."},{"key":"3_CR212","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3324\/haematol.2017.187047","volume":"103","author":"F Boulad","year":"2018","unstructured":"Boulad, F. et al. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica 103, 770\u2013777 (2018).","journal-title":"Haematologica"},{"key":"3_CR213","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3324\/haematol.2018.190876","volume":"103","author":"MM Hsieh","year":"2018","unstructured":"Hsieh, M. M. & Tisdale, J. F. Hematopoietic stem cell mobilization with plerixafor in sickle cell disease. Haematologica 103, 749\u2013750 (2018).","journal-title":"Haematologica"},{"key":"3_CR214","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3324\/haematol.2017.184788","volume":"103","author":"C Lagresle-Peyrou","year":"2018","unstructured":"Lagresle-Peyrou, C. et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica 103, 778\u2013786 (2018).","journal-title":"Haematologica"},{"key":"3_CR215","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood.V130.Suppl_1.689.689","volume":"689","author":"CC Hoppe","year":"2017","unstructured":"Hoppe, C. C. et al. Initial results from a cohort in a phase 2a study (GBT440-007) evaluating adolescents with sickle cell disease treated with multiple doses of GBT440, a HbS polymerization inhibitor. Blood 689, 689 (2017).","journal-title":"Blood"},{"key":"3_CR216","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.278.5339.876","volume":"278","author":"C Paszty","year":"1997","unstructured":"Paszty, C. et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278, 876\u2013878 (1997).","journal-title":"Science"},{"key":"3_CR217","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1126\/science.2154033","volume":"247","author":"TM Ryan","year":"1990","unstructured":"Ryan, T. M. et al. Human sickle hemoglobin in transgenic mice. Science 247, 566\u2013568 (1990).","journal-title":"Science"},{"key":"3_CR218","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc1603499","volume":"375","author":"MM Heeney","year":"2016","unstructured":"Heeney, M. M., Hoppe, C. C. & Rees, D. C. Prasugrel for sickle cell vaso-occlusive events. N. Engl. J. Med. 375, 185\u2013186 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3_CR219","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00005792-199611000-00002","volume":"75","author":"S Charache","year":"1996","unstructured":"Charache, S. et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \u201cswitching\u201d agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine 75, 300\u2013326 (1996).","journal-title":"Medicine"},{"key":"3_CR220","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bcmd.2017.05.009","volume":"70","author":"AI Alayash","year":"2017","unstructured":"Alayash, A. I. Oxidative pathways in the sickle cell and beyond. Blood Cells Mol. Dis. 70, 78\u201386 (2017).","journal-title":"Blood Cells Mol. Dis."},{"key":"3_CR221","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1182\/blood-2009-04-214817","volume":"116","author":"C Sangokoya","year":"2010","unstructured":"Sangokoya, C., Telen, M. J. & Chi, J. T. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 116, 4338\u20134348 (2010).","journal-title":"Blood"},{"key":"3_CR222","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.exphem.2017.02.003","volume":"50","author":"R Jagadeeswaran","year":"2017","unstructured":"Jagadeeswaran, R. et al. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp. Hematol. 50, 46\u201352 (2017).","journal-title":"Exp. Hematol."},{"key":"3_CR223","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1172\/JCI89741","volume":"127","author":"GJ Kato","year":"2017","unstructured":"Kato, G. J., Steinberg, M. H. & Gladwin, M. T. Intravascular hemolysis and the pathophysiology of sickle cell disease. J. Clin. Invest. 127, 750\u2013760 (2017).","journal-title":"J. Clin. Invest."},{"key":"3_CR224","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood-2012-11-451229","volume":"121","author":"DJ Schaer","year":"2013","unstructured":"Schaer, D. J., Buehler, P. W., Alayash, A. I., Belcher, J. D. & Vercellotti, G. M. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 121, 1276\u20131284 (2013).","journal-title":"Blood"},{"key":"3_CR225","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","volume":"122","author":"D Manwani","year":"2013","unstructured":"Manwani, D. & Frenette, P. S. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 122, 3892\u20133898 (2013).","journal-title":"Blood"},{"key":"3_CR226","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1182\/blood-2015-09-667923","volume":"127","author":"BM Dulmovits","year":"2016","unstructured":"Dulmovits, B. M. et al. Pomalidomide reverses \u03b3-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood 127, 1481\u20131492 (2016).","journal-title":"Blood"},{"key":"3_CR227","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2141.2004.05332.x","volume":"128","author":"O Abdulmalik","year":"2005","unstructured":"Abdulmalik, O. et al. 5-Hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br. J. Haematol. 128, 552\u2013561 (2005).","journal-title":"Br. J. Haematol."},{"key":"3_CR228","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1046\/j.1365-2141.2003.04536.x","volume":"122","author":"EW Iyamu","year":"2003","unstructured":"Iyamu, E. W., Turner, E. A. & Asakura, T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br. J. Haematol. 122, 1001\u20131008 (2003).","journal-title":"Br. J. Haematol."},{"key":"3_CR229","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1107\/S0907444911036353","volume":"67","author":"O Abdulmalik","year":"2011","unstructured":"Abdulmalik, O. et al. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallogr. D Biol. Crystallogr. 67, 920\u2013928 (2011).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"3_CR230","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood.V77.6.1334.1334","volume":"77","author":"DJ Abraham","year":"1991","unstructured":"Abraham, D. J. et al. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 77, 1334\u20131341 (1991).","journal-title":"Blood"},{"key":"3_CR231","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.phymed.2008.10.013","volume":"16","author":"B Ouattara","year":"2009","unstructured":"Ouattara, B. et al. Antisickling properties of divanilloylquinic acids isolated from Fagara zanthoxyloides Lam. (Rutaceae). Phytomedicine 16, 125\u2013129 (2009).","journal-title":"Phytomedicine"},{"key":"3_CR232","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1182\/blood.V128.22.3645.3645","volume":"128","author":"MK Safo","year":"2016","unstructured":"Safo, M. K. et al. Vzhe-039, a novel structurally-enhanced allosteric hemoglobin effector inhibits sickling of SS erythrocytes in vitro, and exhibits improved pharmacologic properties in vivo. Blood 128, 3645\u20133645 (2016).","journal-title":"Blood"},{"key":"3_CR233","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1021\/cb500230b","volume":"9","author":"A Nakagawa","year":"2014","unstructured":"Nakagawa, A. et al. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem. Biol. 9, 2318\u20132325 (2014).","journal-title":"ACS Chem. Biol."},{"key":"3_CR234","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI74604","volume":"124","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J. Clin. Invest. 124, 2750\u20132761 (2014).","journal-title":"J. Clin. Invest."},{"key":"3_CR235","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1182\/blood.V94.12.4307","volume":"94","author":"L De Franceschi","year":"1999","unstructured":"De Franceschi, L., Brugnara, C., Rouyer-Fessard, P., Jouault, H. & Beuzard, Y. Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. Blood 94, 4307\u20134313 (1999).","journal-title":"Blood"},{"key":"3_CR236","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1172\/JCI118537","volume":"97","author":"C Brugnara","year":"1996","unstructured":"Brugnara, C. et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J. Clin. Invest. 97, 1227\u20131234 (1996).","journal-title":"J. Clin. Invest."},{"key":"3_CR237","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","volume":"153","author":"KI Ataga","year":"2011","unstructured":"Ataga, K. I. et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br. J. Haematol. 153, 92\u2013104 (2011).","journal-title":"Br. J. Haematol."},{"key":"3_CR238","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1182\/blood-2009-02-204990","volume":"115","author":"RP Hebbel","year":"2010","unstructured":"Hebbel, R. P. et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 115, 2483\u20132490 (2010).","journal-title":"Blood"},{"key":"3_CR239","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/10739680600778456","volume":"13","author":"DK Kaul","year":"2006","unstructured":"Kaul, D. K. et al. Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation. Microcirculation 13, 489\u2013497 (2006).","journal-title":"Microcirculation"},{"key":"3_CR240","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1096\/fj.15-278481","volume":"30","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y., Schwartz, E. A., Palmer, G. M. & Zennadi, R. MEK1\/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease. FASEB J. 30, 1171\u20131186 (2016).","journal-title":"FASEB J."},{"key":"3_CR241","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.lab.2005.02.008","volume":"145","author":"H Mahaseth","year":"2005","unstructured":"Mahaseth, H. et al. Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. J. Lab. Clin. Med. 145, 204\u2013211 (2005).","journal-title":"J. Lab. Clin. Med."},{"key":"3_CR242","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clnu.2009.01.017","volume":"28","author":"VD Martins","year":"2009","unstructured":"Martins, V. D., Manfredini, V., Peralba, M. C. & Benfato, M. S. \u03b1-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients. Clin. Nutr. 28, 192\u2013197 (2009).","journal-title":"Clin. Nutr."},{"key":"3_CR243","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000089472","volume":"115","author":"A El-Beshlawy","year":"2006","unstructured":"El-Beshlawy, A. et al. Diastolic dysfunction and pulmonary hypertension in sickle cell anemia: is there a role for L-carnitine treatment? Acta Haematol. 115, 91\u201396 (2006).","journal-title":"Acta Haematol."},{"key":"3_CR244","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0190-9622(97)70156-7","volume":"37","author":"BE Serjeant","year":"1997","unstructured":"Serjeant, B. E., Harris, J., Thomas, P. & Serjeant, G. R. Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. J. Am. Acad. Dermatol. 37, 491\u2013493 (1997).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3_CR245","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/j.1743-6109.2012.02798.x","volume":"9","author":"B Musicki","year":"2012","unstructured":"Musicki, B., Liu, T., Sezen, S. F. & Burnett, A. L. Targeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penis. J. Sex. Med. 9, 1980\u20131987 (2012).","journal-title":"J. Sexual Med."},{"key":"3_CR246","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.V122.21.977.977","volume":"122","author":"JJ Field","year":"2013","unstructured":"Field, J. J. et al. A phase I single ascending dose study of NKTT120 in stable adult sickle cell patients. Blood 122, 977 (2013).","journal-title":"Blood"},{"key":"3_CR247","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3324\/haematol.2015.124586","volume":"100","author":"BT Kalish","year":"2015","unstructured":"Kalish, B. T. et al. Dietary omega-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica 100, 870\u2013880 (2015).","journal-title":"Haematologica"},{"key":"3_CR248","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3945\/ajcn.112.036319","volume":"97","author":"AA Daak","year":"2013","unstructured":"Daak, A. A. et al. Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 97, 37\u201344 (2013).","journal-title":"Am. J. Clin. Nutr."},{"key":"3_CR249","doi-asserted-by":"publisher","first-page":"H1243","DOI":"10.1152\/ajpheart.00327.2009","volume":"297","author":"JD Beckman","year":"2009","unstructured":"Beckman, J. D. et al. Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. Am. J. Physiol. Heart Circ. Physiol. 297, H1243\u20131253 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"3_CR250","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bjhh.2016.08.004","volume":"39","author":"H Misra","year":"2017","unstructured":"Misra, H. et al. A Phase Ib open label, randomized, safety study of SANGUINATE in patients with sickle cell anemia. Rev. Bras. Hematol. Hemoter 39, 20\u201327 (2017).","journal-title":"Rev. Bras. Hematol. Hemoter"},{"key":"3_CR251","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1182\/blood-2003-08-2969","volume":"103","author":"J Haynes","year":"2004","unstructured":"Haynes, J. et al. Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. Blood 103, 3945\u20133950 (2004).","journal-title":"Blood"},{"key":"3_CR252","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI77250","volume":"126","author":"MS Eiymo Mwa Mpollo","year":"2016","unstructured":"Eiymo Mwa Mpollo, M. S. et al. Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J. Clin. Invest. 126, 571\u2013584 (2016).","journal-title":"J. Clin. Invest."},{"key":"3_CR253","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1086\/677363","volume":"4","author":"M Opene","year":"2014","unstructured":"Opene, M., Kurantsin-Mills, J., Husain, S. & Ibe, B. O. Sickle erythrocytes and platelets augment lung leukotriene synthesis with downregulation of anti-inflammatory proteins: relevance in the pathology of the acute chest syndrome. Pulmonary Circul. 4, 482\u2013495 (2014).","journal-title":"Pulmonary Circul."},{"key":"3_CR254","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117772","volume":"10","author":"JD Belcher","year":"2015","unstructured":"Belcher, J. D. et al. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-\u03baB activation in transgenic sickle mice. PLOS ONE 10, e0117772 (2015).","journal-title":"PLOS ONE"},{"key":"3_CR255","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nature15367","volume":"525","author":"D Zhang","year":"2015","unstructured":"Zhang, D. et al. Neutrophil ageing is regulated by the microbiome. Nature 525, 528\u2013532 (2015).","journal-title":"Nature"},{"key":"3_CR256","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.3324\/haematol.2015.137489","volume":"101","author":"Y Valverde","year":"2016","unstructured":"Valverde, Y., Benson, B., Gupta, M. & Gupta, K. Spinal glial activation and oxidative stress are alleviated by treatment with curcumin or coenzyme Q in sickle mice. Haematologica 101, e44\u2013e47 (2016).","journal-title":"Haematologica"},{"key":"3_CR257","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1055\/s-0038-1661088","volume":"51","author":"MJ Semple","year":"1984","unstructured":"Semple, M. J., Al-Hasani, S. F., Kioy, P. & Savidge, G. F. A double-blind trial of ticlopidine in sickle cell disease. Thromb. Haemostasis 51, 303\u2013306 (1984).","journal-title":"Thromb. Haemostasis"},{"key":"3_CR258","first-page":"199","volume":"15","author":"R Cabannes","year":"1984","unstructured":"Cabannes, R. et al. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents and actions. Supplements 15, 199\u2013212 (1984).","journal-title":"Agents and actions. Supplements"},{"key":"3_CR259","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-3156.2000.00507.x","volume":"5","author":"FU Eke","year":"2000","unstructured":"Eke, F. U., Obamyonyi, A., Eke, N. N. & Oyewo, E. A. An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis. Trop. Med. Int. Health 5, 81\u201384 (2000).","journal-title":"Trop. Med. Int. Health"},{"key":"3_CR260","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.thromres.2013.08.002","volume":"132","author":"PC Desai","year":"2013","unstructured":"Desai, P. C. et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb. Res. 132, 341\u2013345 (2013).","journal-title":"Thromb. Res."},{"key":"3_CR261","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.1175","volume":"68","author":"JB Schnog","year":"2001","unstructured":"Schnog, J. B. et al. Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am. J. Hematol. 68, 179\u2013183 (2001).","journal-title":"Am. J. Hematol."},{"key":"3_CR262","first-page":"CD010155","volume":"12","author":"EJ van Zuuren","year":"2015","unstructured":"van Zuuren, E. J. & Fedorowicz, Z. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Cochrane Database Syst. Rev. 12, CD010155 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"3_CR263","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jama.2011.235","volume":"305","author":"MT Gladwin","year":"2011","unstructured":"Gladwin, M. T. et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 305, 893\u2013902 (2011).","journal-title":"Jama"},{"key":"3_CR264","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/jpet.116.235473","volume":"359","author":"FH Silva","year":"2016","unstructured":"Silva, F. H. et al. Beneficial effect of the nitric oxide donor compound 3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate on dysregulated phosphodiesterase 5, NADPH oxidase, and nitrosative stress in the sickle cell mouse penis: implication for priapism treatment. J. Pharmacol. Exp. Ther. 359, 230\u2013237 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"3_CR265","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.tips.2008.10.003","volume":"30","author":"ZS Katusic","year":"2009","unstructured":"Katusic, Z. S., d\u2019Uscio, L. V. & Nath, K. A. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci. 30, 48\u201354 (2009).","journal-title":"Trends Pharmacol. Sci."},{"key":"3_CR266","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","volume":"118","author":"RF Machado","year":"2011","unstructured":"Machado, R. F. et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 118, 855\u2013864 (2011).","journal-title":"Blood"},{"key":"3_CR267","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2352-3026(14)00019-2","volume":"1","author":"CP Minniti","year":"2014","unstructured":"Minniti, C. P. et al. Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. Lancet Haematol. 1, e95\u2013e103 (2014).","journal-title":"Lancet Haematol."},{"key":"3_CR268","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.V124.21.219.219","volume":"124","author":"JDN Belcher","year":"2014","unstructured":"Belcher, J. D. N. et al. Dimethyl fumarate induces cytoprotection and inhibits vaso-occlusion in transgenic sickle mice. Blood 124, 219 (2014).","journal-title":"Blood"},{"key":"3_CR269","doi-asserted-by":"publisher","first-page":"12169","DOI":"10.1073\/pnas.1509158112","volume":"112","author":"N Keleku-Lukwete","year":"2015","unstructured":"Keleku-Lukwete, N. et al. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proc. Natl Acad. Sci. USA 112, 12169\u201312174 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3_CR270","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.81090","volume":"1","author":"S Ghosh","year":"2016","unstructured":"Ghosh, S. et al. Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice. JCI Insight 1, e81090 (2016).","journal-title":"JCI Insight"},{"key":"3_CR271","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00109-010-0613-6","volume":"88","author":"JD Belcher","year":"2010","unstructured":"Belcher, J. D. et al. Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. J. Mol. Med. 88, 665\u2013675 (2010).","journal-title":"J. Mol. Med."},{"key":"3_CR272","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjh.14280","volume":"175","author":"PA Shi","year":"2016","unstructured":"Shi, P. A. et al. Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. Br. J. Haematol. 175, 714\u2013723 (2016).","journal-title":"Br. J. Haematol."},{"key":"3_CR273","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2015-08-663245","volume":"127","author":"F Vinchi","year":"2016","unstructured":"Vinchi, F. et al. Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood 127, 473\u2013486 (2016).","journal-title":"Blood"},{"key":"3_CR274","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/nat.2010.0270","volume":"21","author":"AD Burnette","year":"2011","unstructured":"Burnette, A. D. et al. RNA aptamer therapy for vaso-occlusion in sickle cell disease. Nucleic Acid. Ther. 21, 275\u2013283 (2011).","journal-title":"Nucleic Acid. Ther."},{"key":"3_CR275","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2010-05-285718","volume":"117","author":"DR Gutsaeva","year":"2011","unstructured":"Gutsaeva, D. R. et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood 117, 727\u2013735 (2011).","journal-title":"Blood"},{"key":"3_CR276","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1096\/fj.07-098921","volume":"22","author":"L De Franceschi","year":"2008","unstructured":"De Franceschi, L. et al. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J. 22, 1849\u20131860 (2008).","journal-title":"FASEB J."},{"key":"3_CR277","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0002-9343(99)80341-6","volume":"98","author":"RY Aoki","year":"1995","unstructured":"Aoki, R. Y. & Saad, S. T. Enalapril reduces the albuminuria of patients with sickle cell disease. Am. J. Med. 98, 432\u2013435 (1995).","journal-title":"Am. J. Med."},{"key":"3_CR278","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0002-9343(98)00056-4","volume":"104","author":"L Foucan","year":"1998","unstructured":"Foucan, L. et al. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am. J. Med. 104, 339\u2013342 (1998).","journal-title":"Am. J. Med."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-018-0003-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-018-0003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-018-0003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:52:11Z","timestamp":1775292731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-018-0003-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":278,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1038\/s41573-018-0003-2","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]},"assertion":[{"value":"4 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.T., P.M. and G.M.V. have been involved in clinical and\/or basic research involving multiple compounds and therapeutic strategies discussed in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}